No Data
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) has had its application for a simplified equity offering for the 2024 fiscal year approved by the Shanghai Stock Exchange.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that the company received a notice from the Shanghai Exchange on March 12, 2025 regarding...
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): Shareholder Bai Ying has cumulatively reduced her shareholding by 0.58%.
On March 10, Gelonghui reported that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that the company recently received a notice letter regarding the shareholding reduction results from shareholder Ms. Bai Ying. During the shareholding reduction plan period, Ms. Bai Ying cumulatively reduced her holdings by 1,100,000 shares through bulk trading, accounting for 0.58% of the company's total shares. After this reduction, Ms. Bai Ying and her concerted actors together hold 15,167,159 shares in the company, accounting for 8.002% of the total shares. As of the date of this announcement, the implementation period of this shareholding reduction plan has expired.
Research Reports to Uncover Opportunities | HAITONG SEC: Assigning Eyebright Medical Technology (Beijing) Co., Ltd. an "Outperform Market" rating, Target Price 89.30-108.16 yuan.
HAITONG SEC's Research Reports indicate that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) is expected to achieve a net income of 0.387 billion yuan (+27.36%) for the year 2024, with a net income excluding non-recurring items of 0.389 billion yuan (+34.58%). In 2024, the company's series of artificial lenses 'Punomeng' and 'Punotong' shaped corneal lenses are expected to maintain year-on-year income growth, while vision care products (such as contact lenses and contact lens care products) continue to grow rapidly, accounting for about 30% of revenue. The increase in revenue has driven the growth of the company's net income, and the contact lens business has turned profitable; however, it is affected by the price decrease following the centralized procurement of artificial lenses.
Aibo Healthcare: 688050 Aibo Healthcare 2024 Annual Performance Report
688050 Aibo Healthcare 2024 Annual Performance Report
In the fourth quarter, Eyebright Medical Technology (Beijing) Co., Ltd. saw a more than 30% decline in net profit compared to the previous quarter, due to a decrease in the prices of products under centralized purchasing and changes in revenue structure p
① The company's series of artificial lenses such as 'Punoming' and 'Punotong' corneal reshaping lenses have maintained year-on-year growth in revenue, while vision care products continue to grow rapidly, accounting for about 30% of revenue. ② The company's contact lens Business has turned losses into profits, and it is increasing related production capacity. After the completion of the fundraising investment project, an annual production capacity of 0.252 billion contact lenses and 500 million pairs of molds will be formed.
